These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

615 related items for PubMed ID: 26160970

  • 1. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
    Sucher AJ, Chahine EB, Cogan P, Fete M.
    Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ceftolozane-tazobactam: A new-generation cephalosporin.
    Cluck D, Lewis P, Stayer B, Spivey J, Moorman J.
    Am J Health Syst Pharm; 2015 Dec 15; 72(24):2135-46. PubMed ID: 26637512
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I, Maraolo AE, Borgia G.
    Expert Rev Anti Infect Ther; 2016 Oct 15; 14(10):875-8. PubMed ID: 27599088
    [No Abstract] [Full Text] [Related]

  • 9. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK.
    Int J Antimicrob Agents; 2018 Feb 15; 51(2):181-189. PubMed ID: 28993143
    [Abstract] [Full Text] [Related]

  • 10. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
    Eckmann C, Solomkin J.
    Expert Opin Pharmacother; 2015 Feb 15; 16(2):271-80. PubMed ID: 25529765
    [Abstract] [Full Text] [Related]

  • 11. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C.
    Clin Infect Dis; 2015 May 15; 60(10):1462-71. PubMed ID: 25670823
    [Abstract] [Full Text] [Related]

  • 12. Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections.
    Skalweit MJ.
    Drug Des Devel Ther; 2015 May 15; 9():2919-25. PubMed ID: 26082619
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.
    Wagenlehner FM, Alidjanov JF.
    Expert Opin Drug Metab Toxicol; 2016 Aug 15; 12(8):959-66. PubMed ID: 27327964
    [Abstract] [Full Text] [Related]

  • 17. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
    Xipell M, Bodro M, Marco F, Martínez JA, Soriano A.
    Future Microbiol; 2017 Nov 15; 12():1323-1326. PubMed ID: 28980834
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE.
    Antimicrob Agents Chemother; 2016 Jan 15; 60(1):515-21. PubMed ID: 26552975
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.